ZEULIDE DEPOT 3.75 MG
LEUPROLIDE ACETATE : 3.75 MG · DIN 02429977 · VERITY PHARMACEUTICALS INC.
Health Canada status: MARKETED
What is ZEULIDE DEPOT?
ZEULIDE DEPOT 3.75 MG contains LEUPROLIDE ACETATE : 3.75 MG. It is listed in the Health Canada Drug Product Database under DIN 02429977, held by VERITY PHARMACEUTICALS INC., supplied as POWDER FOR SUSPENSION, SUSTAINED-RELEASE ; KIT for INTRAMUSCULAR administration. Health Canada currently lists it as marketed, status dated 08-Oct-2019. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is ZEULIDE DEPOT used for?
Palliative treatment of advanced and/or metastatic prostate cancer.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02429977 |
|---|---|
| Brand name | ZEULIDE DEPOT |
| Generic / active ingredient | LEUPROLIDE ACETATE : 3.75 MG |
| Manufacturer | VERITY PHARMACEUTICALS INC. |
| Strength | 3.75 MG |
| Dosage form | POWDER FOR SUSPENSION, SUSTAINED-RELEASE ; KIT |
| Route of administration | INTRAMUSCULAR |
| Schedule | Prescription |
| ATC code | L02AE02 LEUPRORELIN |
| AHFS class | 24:12.12 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 08-Oct-2019 |
How is it administered?
Administered by a healthcare professional via intramuscular injection. 3.75 mg monthly or 22.5 mg every 3 months. Reconstitute with provided diluent immediately before use.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
The product must be brought to room temperature before administration. (Specific temperature range not provided in text snippet, but standard clinical storage applies).
How is it supplied?
Single dose kits containing one vial of medicinal ingredient, one prefilled syringe with 2 mL diluent, and one adaptor system with a 21G safety needle.
Contraindications
Hypersensitivity to LH-RH or analogs; women who are or may become pregnant; nursing mothers.
Warnings and precautions
Serious warnings: Clinical testosterone flare, osteoporosis/decreased bone density, sudden cardiac death, pituitary apoplexy, and drug-induced liver injury. Risk of QT prolongation.
What can be used instead?
Other Canadian products sharing ATC code L02AE02 LEUPRORELIN. 11 of 16 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ELIGARD | 22.5 MG | POWDER FOR SUSPENSION, SUSTAINED-RELEASE | TOLMAR INTERNATIONAL LTD. | MARKETED | DIN 02248240 |
| ELIGARD | 30 MG | POWDER FOR SUSPENSION, SUSTAINED-RELEASE | TOLMAR INTERNATIONAL LTD. | MARKETED | DIN 02248999 |
| ELIGARD | 45 MG | POWDER FOR SUSPENSION, SUSTAINED-RELEASE | TOLMAR INTERNATIONAL LTD. | MARKETED | DIN 02268892 |
| ELIGARD | 7.5 MG | POWDER FOR SUSPENSION, SUSTAINED-RELEASE | TOLMAR INTERNATIONAL LTD. | MARKETED | DIN 02248239 |
| LUPRON DEPOT | 11.25 MG | POWDER FOR SUSPENSION, SUSTAINED-RELEASE | ABBVIE CORPORATION | MARKETED | DIN 02239834 |
| LUPRON DEPOT | 22.5 MG | POWDER FOR SUSPENSION, SUSTAINED-RELEASE | ABBVIE CORPORATION | MARKETED | DIN 02230248 |
| LUPRON DEPOT | 3.75 MG | POWDER FOR SUSPENSION, SUSTAINED-RELEASE | ABBVIE CORPORATION | MARKETED | DIN 00884502 |
| LUPRON DEPOT | 30 MG | POWDER FOR SUSPENSION, SUSTAINED-RELEASE | ABBVIE CORPORATION | MARKETED | DIN 02239833 |
| LUPRON DEPOT | 7.5 MG | POWDER FOR SUSPENSION, SUSTAINED-RELEASE | ABBVIE CORPORATION | MARKETED | DIN 00836273 |
| ZEULIDE DEPOT | 22.5 MG | POWDER FOR SUSPENSION, SUSTAINED-RELEASE ; KIT | VERITY PHARMACEUTICALS INC. | MARKETED | DIN 02462699 |
Who else supplies LEUPRORELIN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. LEUPRORELIN appears in 76 registered pack listings across 11 markets, published on 9 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.